(Q45249085)

11 December 2017

title

Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours (English)

1 reference

11 December 2017

F Forrer

1

1 reference

11 December 2017

J Mueller-Brand

series ordinal

2

1 reference

11 December 2017

H Maecke

series ordinal

3

1 reference

11 December 2017

publication date

1 April 2005

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

11 December 2017

published in

1 reference

11 December 2017

volume

32

1 reference

11 December 2017

issue

4

1 reference

11 December 2017

page(s)

511-2; author reply 513

1 reference

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

11 December 2017

cites work

1 reference

12 December 2020

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

12 December 2020

A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy

1 reference

12 December 2020

Is the Renal Dosimetry for [90Y-DOTA0, Tyr3]Octreotide Accurate Enough to Predict Thresholds for Individual Patients?

1 reference

12 December 2020

90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies

1 reference

12 December 2020

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

1 reference

12 December 2020

Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide.

1 reference

12 December 2020

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

1 reference

12 December 2020

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

1 reference

12 December 2020

Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

12 December 2020

10.1007/S00259-004-1726-3

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

1010363171

0 references

1 reference